In mouse xenografts of human RCC, the combination of lenvatinib and everolimus inhibited the human endothelial cell growth, tube formation, VEGF signaling and tumor growth more than each drug alone [9,25,26]. Here, VEGFA is linked to renal cell carcinoma.